CONSORTIUM CALL 2026
Our pharma partners in the Milner Therapeutics Consortium work together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing and 6-month pilots to 2-year postdoctoral funded collaborations and are expected to lead to joint publications with the company partners.
The annual Consortium Call runs from January to March each year, and seeks project proposals for challenges in areas such as:
- Oncology
- Neuroscience
- Immunology and inflammation
- New technologies that will aid therapeutic discovery
- Metabolic and cardiovascular disease
- Dermatology
- Infectious disease
Last year, the Consortium Call offered the following items for successful projects:
- Expertise e.g. in particular techniques, disease areas, target selection and validation
- Support for pilot (e.g. 6-12 months) or longer-term projects (2-3 years)
- Funding e.g. for a research associate and consumables
- Access to company reagents where appropriate e.g. tool compounds, compound libraries
The Consortium Call is a competitive process; although many proposals will not result in a funded project in the short term, these introductions are a good opportunity to make connections and build a relationship with pharma partners, as well as to receive useful feedback from the pharma perspective.
Contact us
If you have any questions, please email consortium@milner.cam.ac.uk